Skandinaviska Enskilda Banken Ab (Publ) Fate Therapeutics Inc Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$9.86 - $23.83 $19,443 - $46,992	-1,972 Reduced 0.63%	309,359 $3.12 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $2.48 Million - $4.24 Million	117,694 Added 60.78%	311,331 $6.98 Million
Q2 2022 Aug 10, 2022	BUY	$17.78 - $42.39 $231,442 - $551,790	13,017 Added 7.21%	193,637 $4.8 Million
Q1 2022 May 11, 2022	BUY	$29.67 - $60.28 $205,197 - $416,896	6,916 Added 3.98%	180,620 $7 Million
Q4 2021 Feb 10, 2022	BUY	$47.84 - $64.34 $1.52 Million - $2.04 Million	31,753 Added 22.37%	173,704 $10.4 Million
Q2 2021 Aug 10, 2021	BUY	$67.25 - $92.52 $8.03 Million - $11 Million	119,351 Added 528.1%	141,951 $12.3 Million
Q4 2020 Feb 11, 2021	BUY	$38.09 - $100.95 $571,350 - $1.51 Million	15,000 Added 197.37%	22,600 $2.06 Million
Q3 2020 Nov 12, 2020	SELL	$30.41 - $40.5 $495,683 - $660,150	-16,300 Reduced 68.2%	7,600 $304,000
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $483,019 - $841,996	23,900 New	23,900 $820,000

177

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $126M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.